



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Appln. No Confirmation 1 U.S. Filing Da	te : 09/16/2003 ion : Potent Inhibitor of HCV Seri	) Art Unit: ) Examiner: ne Protease	Not Yet Assigned
Commissioner P. O. Box 145 Alexandria, V			
September 13,	2004		
TRANSMI	ITTAL LETTER FOR INFORM	ATION DISCL	OSURE STATEMENT
Sir:			
	erewith concerning the subject appl rm 1449A/B) under 37 C.F.R. §§1.:		
§1.53 (d); ii) w 37 C.F.R. §1.4 on the merits;	This Statement is being file nal application other than a continuvithin three (3) months of the date of 191 in an international application; if or iv) before the mailing of a first Commination under 37 C.F.R. §1.114.	ed prosecution ap of entry of the nat (ii) before the ma	pplication under 33 C.F.R. ional stage as set forth in iling of a first Office action
notice of allow	This Statement is being file o), but before the mailing date of: i) vance under 37 C.F.R. §1.311, or iii ion. This Statement is being accommoder accommode	a final action un ) an action that o	der 37 C.F.R. §1.113, ii) a
	A statement as specified in 37 C.F	F.R. §1.97(e) [see	below]; or
	The fee set forth in 37 C.F.R. §1.1	7(p).	
	The Commissioner is hereb \$180.00 fee set forth in 37 C.F.R.	_	<del>-</del>

		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
	ent as s	This Statement is being filed after the period specified in 37 C.F.R. on or before payment of the issue fee. This Statement is accompanied by a pecified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	1.97(e	).
	counte	Each item of information contained in the instant information disclosure tent was first cited in any communication from a foreign patent office in a expart foreign application not more than three (3) months prior to the filing of the tinformation disclosure statement; or
	foreign makin inform §1.56(	No item of information contained in the instant information disclosure tent was cited in a communication from a foreign patent office in a counterpart in application, and, to the knowledge of the person signing this certification after greasonable inquiry, no item of information contained in the instant nation disclosure statement was known to any individual designated in 37 C.F.R. (c) more than three (3) months prior to the filing of the instant information sure statement.
		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
counte in sect	rpart ap	d). Each item of information contained in the accompanying information tement was cited in a communication from a foreign patent office in a oplication, which communication was not received by any individual designated 6(c) more than thirty (30) days prior to the filing of the accompanying isclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Philip I. Datlow

Attorney for Applicant(s)

Reg. No. 41,482

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4542 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on September 13, 2004.

Philip I. Datlow, Reg. No. 41,482

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

Complete if Known				
Application Number	10/663,220			
Filing Date	09/16/2003			
First Named Inventor	Shirlynn CHEN			
Art Unit	1646			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	0/260			

(Use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket Number 9/260

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		<sup>US-</sup> US2003195228	10-16-2003	Shirlynn CHEN, et al.	
		<sup>US-</sup> 6,608,027	08-19-2003	Youla S. TSANTRIZOS, et al.	
		US-			
	ļ	US-			
	<u> </u>	US-			
	<b></b>	US-			
		US-			
		US-			
<del></del>		US-			
		US-			
·		US-			
<del></del>		US-			
		US-	-		
		US-			

-	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	  -6		
miliais	140.	Country Code <sup>3</sup> 'Number <sup>4</sup> 'Kind Code <sup>5</sup> (if known)	IVIIVI-DD-1111	Applicant of Oiled Document	or Relevant Figures Appear	Ľ		
		WO 03/066103 A1	08-14-2003	Boehringer Ingelheim Pharmaceuticals, Inc.				
		WO 00/59929	10-12-2000	Boehringer Ingelheim (Canada) Ltd.		Г		
••••••••	1				}*************************************			
	1				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
·····	İ			•	·	Г		

Examiner	" - '	Date	
Signature		Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for	form 1449B/PTO			Complete if Known			
					Application Number	10/663,220		
	INFO	RMATION DI	SCLO	SURE	Filing Date	09/16/2003		
STATEMENT BY APPLICANT					First Named Inventor	Shirlynn CHEN		
					Art Unit	1646		
		(Use as many sheets as	necessary	)	Examiner Name	Not Yet Assigned		
	Sheet	2	of	2	Attorney Docket Number	9/260		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		"Europe Holds Less Allure for Boehringer", Current Drug Discovery, Pharma Press, London, GB; June 2002 (2002-06), pgs 45-46.	
	**********		
	•••••••		
•••••••	••••••••••		
	*************		
	***************************************		
	•••••••••••••••••••••••••••••••••••••••	<u></u>	
Examiner		Date .	

ſ	1	
Examiner	Date .	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.